Dayna E McGill1, Lisa K Volkening1, David M Pober1, Andrew B Muir2, Deborah L Young-Hyman3, Lori M Laffel4. 1. Section on Clinical, Behavioral, and Outcomes Research, Pediatric, Adolescent, and Young Adult Section, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts. 2. Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia. 3. Georgia Prevention Institute, Georgia Health Sciences University, Augusta, Georgia. 4. Section on Clinical, Behavioral, and Outcomes Research, Pediatric, Adolescent, and Young Adult Section, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts. Electronic address: lori.laffel@joslin.harvard.edu.
Abstract
PURPOSE: Depressive symptoms occur at various times during the life cycle in persons with type 1 diabetes. We investigated depressive symptoms prospectively in youth with new-onset type 1 diabetes and in those beginning pump therapy. METHODS: Youth with type 1 diabetes (N = 96), ages 10-17 years, completed the Children's Depression Inventory (CDI) at baseline and at 1, 6, and 12 months after diabetes onset or pump start; scores ≥13 indicated clinical elevation. The change in depressive symptoms and the association between CDI score and hemoglobin A1c (HbA1c) level were assessed over 1 year. RESULTS: The new-onset group (n = 54) had an HbA1c level of 11.4% ± 2.5%. The pump group (n = 42) had a diabetes duration of 4.1 ± 3.4 years and an HbA1c level of 8.3% ± 1.3%. The baseline median CDI was 5.0 in both groups and remained low over time (ranging from 2.0 to 3.5). Most youth (new onset 72%, pump 81%) scored <13 at all times. Those with a CDI score of ≥13 in month 1 had 9-fold (95% confidence interval: 3-28) and 11-fold (95% confidence interval: 3-38) higher risks of CDI score of ≥13 at 6 and 12 months, respectively, than those with a CDI score of <13. New-onset youth with a CDI score of ≥13 in month 1 had a higher HbA1c level at 6 months (8.3% ± 1.7%) than new-onset youth with a CDI score of <13 (7.2% ± 1.6%, p = .04). CONCLUSIONS: CDI scores over 1 year were similar in the new-onset and pump groups. Youth with elevated CDI in the first month after diagnosis or pump start were significantly more likely to have a CDI score of ≥13 at 6 or 12 months, supporting recommendations to screen for depressive symptoms because of persistence over time. Those with new-onset diabetes and depressive symptoms in the first month had higher HbA1c at 6 months; confirmatory research is needed.
PURPOSE:Depressive symptoms occur at various times during the life cycle in persons with type 1 diabetes. We investigated depressive symptoms prospectively in youth with new-onset type 1 diabetes and in those beginning pump therapy. METHODS: Youth with type 1 diabetes (N = 96), ages 10-17 years, completed the Children's Depression Inventory (CDI) at baseline and at 1, 6, and 12 months after diabetes onset or pump start; scores ≥13 indicated clinical elevation. The change in depressive symptoms and the association between CDI score and hemoglobin A1c (HbA1c) level were assessed over 1 year. RESULTS: The new-onset group (n = 54) had an HbA1c level of 11.4% ± 2.5%. The pump group (n = 42) had a diabetes duration of 4.1 ± 3.4 years and an HbA1c level of 8.3% ± 1.3%. The baseline median CDI was 5.0 in both groups and remained low over time (ranging from 2.0 to 3.5). Most youth (new onset 72%, pump 81%) scored <13 at all times. Those with a CDI score of ≥13 in month 1 had 9-fold (95% confidence interval: 3-28) and 11-fold (95% confidence interval: 3-38) higher risks of CDI score of ≥13 at 6 and 12 months, respectively, than those with a CDI score of <13. New-onset youth with a CDI score of ≥13 in month 1 had a higher HbA1c level at 6 months (8.3% ± 1.7%) than new-onset youth with a CDI score of <13 (7.2% ± 1.6%, p = .04). CONCLUSIONS:CDI scores over 1 year were similar in the new-onset and pump groups. Youth with elevated CDI in the first month after diagnosis or pump start were significantly more likely to have a CDI score of ≥13 at 6 or 12 months, supporting recommendations to screen for depressive symptoms because of persistence over time. Those with new-onset diabetes and depressive symptoms in the first month had higher HbA1c at 6 months; confirmatory research is needed.
Authors: Steven M Willi; Kellee M Miller; Linda A DiMeglio; Georgeanna J Klingensmith; Jill H Simmons; William V Tamborlane; Kristen J Nadeau; Julie M Kittelsrud; Peter Huckfeldt; Roy W Beck; Terri H Lipman Journal: Pediatrics Date: 2015-03 Impact factor: 7.124
Authors: L Lichtenberger-Geslin; B Boudailliez; K Braun; V Bach; A Mercier; H Bony-Trifunovic Journal: Arch Pediatr Date: 2013-02-04 Impact factor: 1.180
Authors: Korey K Hood; Daniel P Beavers; Joyce Yi-Frazier; Ronny Bell; Dana Dabelea; Robert E Mckeown; Jean M Lawrence Journal: J Adolesc Health Date: 2014-05-10 Impact factor: 5.012
Authors: Lawrence Fisher; William H Polonsky; Danielle M Hessler; Umesh Masharani; Ian Blumer; Anne L Peters; Lisa A Strycker; Vicky Bowyer Journal: J Diabetes Complications Date: 2015-02-07 Impact factor: 2.852
Authors: A Kokoszka; F Pouwer; A Jodko; R Radzio; P Mućko; J Bieńkowska; E Kuligowska; O Smoczyńska; Z Skłodowska Journal: Eur Psychiatry Date: 2009-06-21 Impact factor: 5.361
Authors: Deborah Young-Hyman; Mary de Groot; Felicia Hill-Briggs; Jeffrey S Gonzalez; Korey Hood; Mark Peyrot Journal: Diabetes Care Date: 2016-12 Impact factor: 19.112
Authors: Shelagh A Mulvaney; Constance A Mara; Jessica C Kichler; Shideh Majidi; Kimberly A Driscoll; Sarah C Westen; Alana Rawlinson; Laura M Jacobsen; Rebecca N Adams; Korey K Hood; Maureen Monaghan Journal: Transl Behav Med Date: 2021-02-11 Impact factor: 3.046
Authors: Kara R Harrington; Amit Shapira; Lisa K Volkening; Deborah A Butler; Barbara J Anderson; Rachel M Wasserman; Lori M Laffel Journal: J Diabetes Complications Date: 2021-01-06 Impact factor: 2.852
Authors: Ryan M Hill; Katherine A S Gallagher; Sahar S Eshtehardi; Serife Uysal; Marisa E Hilliard Journal: Curr Diab Rep Date: 2021-12-13 Impact factor: 4.810
Authors: Maureen Monaghan; Constance A Mara; Jessica C Kichler; Sarah C Westen; Alana Rawlinson; Laura M Jacobsen; Rebecca N Adams; Jenine Y Stone; Korey K Hood; Shelagh A Mulvaney Journal: Can J Diabetes Date: 2021-01-22 Impact factor: 2.774